|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2000032819 |
|
最近更新日期: Date of Last Refreshed on: |
2020-05-12 03:23:37 |
|
注册时间: Date of Registration: |
2020-05-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国耳硬化流行病学多中心调查研究 |
|
Public title: |
An epidemiology of otosclerosis in China:a multi-center survey |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国耳硬化临床流行病学多中心调查研究 |
|
Scientific title: |
An epidemiology of otosclerosis in China:a multi-center survey |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
舒易来 |
研究负责人: |
舒易来 |
|
Applicant: |
Yilai Shu |
Study leader: |
Yilai Shu |
|
申请注册联系人电话: Applicant telephone: |
+86 15900519196 |
研究负责人电话: Study leader's telephone: |
+86 15900519196 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yialishu@163.com |
研究负责人电子邮件: Study leader's E-mail: |
yialishu@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市徐汇区汾阳路83号 |
研究负责人通讯地址: |
上海市徐汇区汾阳路83号 |
|
Applicant address: |
83 Fenyang Road, Xuhui District, Shanghai, China |
Study leader's address: |
83 Fenyang Road, Xuhui District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属眼耳鼻喉科医院 |
||
|
Applicant's institution: |
Eye & ENT Hospital of Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属眼耳鼻喉科医院 |
||
|
Affiliation of the Leader: |
Eye & ENT Hospital of Fudan University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020035 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属眼耳鼻喉科医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Eye, Ear, Nose and Throat Hospital of Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-04-30 00:00:00 |
||
|
伦理委员会联系人: |
闫晶超 |
||
|
Contact Name of the ethic committee: |
Jinchao Yan |
||
|
伦理委员会联系地址: |
上海市徐汇区汾阳路83号10号楼305室 |
||
|
Contact Address of the ethic committee: |
Office 305, 10th Floor, 83 Fenyang Road, Xuhui District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
复旦大学附属眼耳鼻喉科医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Eye & ENT Hospital of Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市徐汇区汾阳路83号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
83 Fenyang Road, Xuhui District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
医院“双优”项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hospital Double Excellent Project |
||||||||||||||||||||||
|
Target disease: |
otosclerosis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
流行病学研究 |
||||||||||||||||||||||
|
Study type: |
Epidemilogical research |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1.通过全国多中心调研,研究中国人耳硬化患者临床患病率、人口分布、性别、家族史等流行病学资料。 2.通过全国多中心颞骨组织标本,研究中国人组织耳硬化流行病学数据资料。 3.对全国范围内多中心耳硬化患者进行听力学一级伴随症状等分析,研究中国人耳硬化患者症状、伴随症状分析。 4.通过对各中心诊治的耳硬化患者手术方式、镫骨假体测量长度、术后效果评价,探究中国人耳硬化治疗效果相关参数。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To study the clinical prevalence, population distribution, gender, family history and other epidemiological data of otosclerosis patients in China with multi-center survey. 2. To study the epidemiological data of otosclerosis in China with multi-center survey. 3.To study the symptoms and concomitant symptoms of Chinese patients with otosclerosis. 4.To explore the parameters related to the therapeutic effect of Chinese patients with otosclerosis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
按照耳硬化诊断标准纳入研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
patients meet with the diagnostic criteria of otosclerosis. |
||||||||||||||||||||||
|
排除标准: |
对于急、慢性中耳炎症性疾病、内耳疾病、以及听骨链畸形等先天性疾病所导致的听力损失予排除。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients with acute and chronic inflammatory diseases of middle ear, inner ear diseases and congenital diseases such as ossicular chain malformation were excluded. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-06-01 00:00:00至 To 2023-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-06-01 00:00:00 至 To 2022-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
N/A |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
发表学术论文或临床试验公共管理平台ResMan(http://www.medresman.org.cn) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Published academic paper or available in clinical trials public management platform ResMan (http://www.medresman.org.cn) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |